Serum C-reactive protein levels in severe and very severe pneumonia in children
Abstract
Background Pneumonia is a major cause of death in children from
developing countries. It is difficult to assess pneumonia severity if
clinical symptoms of pneumonia are unclear, co-morbidities occur
simultaneously, or there is an absence of consolidation or infiltrates
on chest radiograph. Examination of C-reactive protein (CRP)
levels can help to determine the severity of pneumonia.
Objective To compare serum CRP levels in severe and very severe
pneumonia cases.
Methods This was a cross-sectional study on pediatric patients
aged> 28 days up to 60 months v.ith a diagnosis of severe or very
severe pneumonia. Subjects were hospitalized at the Department
of Child Health, Udayana University Medical SchooliSanglah
Hospital, Denpasar from May 2010 to January 2011. There were
30 subjects in each group, severe or very severe pneumonia. Data
were analyzed using Mann-Whitney and ANCOVA tests with
statistical significance set at P < 0.05.
Results There were significant differences in median serum CRP
levels in the severe and very severe pneumonia groups. The very
severe pneumonia group had a median CRP level of 54.75 mgiL
(lQrange 0.22 to 216.00) and the severe pneumonia group had a
median CRP level ofl6.06 mgiL (IQ range 0.97 to 89.35). Serum
CRP levels were influenced by the severity of pneumonia (P =
0.002) and the timing of the CRP examination (P = 0.001).
Conclusion Subjects with very severe pneumonia had
significantly higher median CRP level compared to that of subjects
with severe pneumonia. [Paediatr Indones. 2012;52:161A].
References
DB. editors.B uku ajar respirologi anak.1 st ed.J akarta: Badan
Penerbit IDA!; 2008. p. 350·65.
2. Pourcyrous M, Bada HS, Korones SB, Baselski V, Wong
SP. Significance of serial C-reactive protein responses
in neonatal infection and other disorders. Pediatrics.
1993;920431.5.
3. Almiral J. Bolbar I. Toran P, Pera G. Boquet X. Balamo X, et
al. Contribution of C-reactive protein to the diagnosis and
assessment of severity of community-acquired pneumonia.
Chest. 2004;12501335·42.
4. Deodhare SG. C-reactive protein: clinical applications.
Pathology, Microbiology and Clinical Pathology Series.
2 001;1:1-16.
5. Requejo HIZ, Cocozoa AM. C-reactive protein in the
diagnosis of community-acquired pneumonia. Braz J Infect
Dis.2003;N41·4.
6. Singanayagam A, Chalmers JD, Hill AT Severity assessment
in community-acquired pneumonia: a review. QJM.
2009;102.379·88.
7. Juan X. Lu Y. Shi J. Deng X. Long W. Visfatin levels in
patients with severe pneumonia. World J Emerg Med.
2011;2.132·6.
8. Bircan A, K aya 0, Gokirmak M, Ozturk 0, S ahin U, Akkaya
A. C-reactive protein, leukocyte count and ESR in the
assessment of severity of community-acquired pneumonia.
Tuberk Toraks. 2006;54>22·9.
9. Kolsuz M, Erginel S, Alatas 0, Alatas F. Metintas M, Uc-gun I, et al. Acute phase reactants and cytokine levels in
unilateral community-acquired pneumonia. Respiration.
2003;70.615·22.
10. Van der Meer V, Neven AK, Van den Broek P, Assendelfr
WJ. Diagnostic value of C reactive protein in infections
of the lower respiratory tract: systematic review. BM].
2005;331;26.
11. Arimon Z, Peisakh A, Schrire S, Berner Y. C-reactive
protein (CRP): an important diagnostic and prognostic tool
in nursing-home-associated pneumonia. Arch Gerontol
Getiatr.2011;53.364·9.
12. Hohenthal U, Hurme S, Halenius H, Heiro M, Meurman
0, Nikoskelainen ], et al. Utility of C-reactive protein
in assessing the disease severity and complications of
community-acquired pneumonia. Clin Microbiol Infect.
2009;15.1026·32.
13. Lauritzen B, Lykkesfeldt J, Skaanild MT, A n ge n 0,
Nielson JP, Friss C. Putative biomarkers for evaluating
antibiotic treatment: an experimental model of porcine
Actinobacillus pleuropneumoniae infection in pigs. Res Vet
Sci. 2003;74.261·70.
14. Bruns AHW, Oosterheert J], Hak E, Hoepelman AIM.
Usefulness of consecutive C-reactive protein measurements
in follow-up of severe community-acquired pneumonia.E ur
Respir J. 2008;32.726·32.
15. Hirchhfield GM, Pepys MB. C-reactive protein and
cardiovascular disease: new insights from an old molecule.
QjM.2003;96.793.807.
16. Melbye H, Stocks N. Point of care testing for C-reactive
protein. Aust Fam Physician. 2006;35:513-7.
17. Dowd JM, Zajacova A, Aiello A. Predictors of in Ram matio n
in U.S child ren aged 3-16 years. Am J P r ey Med.
2010;39;314·20.
Authors who publish with this journal agree to the following terms:
Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal.
Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal.
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Accepted 2016-08-30
Published 2012-06-30
